Another successful example is the AS1411 aptamer targeting nucleolin, which is currently in phase II clinical trials for treating acute myeloid leukaemia (AML) and metastatic renal cell carcinoma (MRCC) [243,244,245]. The gene discussed is NUCLEOLIN; the disease is acute myeloid leukemia.